Treatment of the commercially available 3-methoxyphenylacetonitrile (6) with sodium bis (trimethylsilyl)amide and subsequent cyclobisalkylation with , -dibromo or dichloroalkanes in THF at 0 o C produces adducts 7a-d , which serve as precursors to the new conformationally constrained phenylalkylamides 5a-h . Compounds 5a-f are melatonin receptor agonists in the Xenopus laevis melanophore assay and their potency depends on both the size of the R group and the size and shape of the -substituent. The fact that the cyclohexano-substituted analogs 5g and 5h are, regardless of the size of the R group, melatonin receptor antagonists, implies that the nature of the -substituent constitutes a functional probe in the receptor's dynamic agonist-antagonist conformational equilibrium.Keywords: N-acyl 1-(3-methoxyphenyl)cycloalkanomethanamines, design, synthesis, melatoninergic activity.Melatonin (N-acetyl-5-methoxytryptamine, 1), the hormone secreted by the pineal gland, is a major component in the control of circadian rhythms in humans and other animals [1,2]. Since the identification of three distinct melatonin receptor subtypes [3][4][5][6][7] there have been numerous studies in an attempt to understand how melatonin interacts with its receptors. the side chain by acting as both hydrogen bond donor and acceptor, provided that it is capable of spending ample time in the preferred binding conformation [11]. One way of accomplishing this is by introducing -substituents in the 3-N-acetyl ethylamine side chain of melatonin, forcing it to orientate orthogonally to the plane of the indole ring. As a result the population of the preferred conformation is sufficiently increased [8]. The proton donor NH indole is not essential for binding, as has been demonstrated by various A number of structure-activity relationships have been identified [8] and recently we and other researchers have N H NHCOCH 3 H 3 CO N H NHCOCH 3 O NHCOR 1: melatonin 3: R=n-C 3 H 7 (pEC 50 =8.32 [11]) 4: luzindole 2: R=C 2 H 5 (pEC 50 =8.28 [11])proposed molecular models of the melatonin binding site: the key elements for high binding affinity are the presence and the relative spatial position of the methoxy group and the N-alkanamido side chain linked to an appropriate spacer [9,10]. The methoxy group highly enhances binding affinity by forming a hydrogen bond with His211 in the putative transmembrane domain 5 (TM5) of the receptor [11,12], and potent heterocyclic bioisosters of indoles [13][14][15][16][17][18], and our earlier findings using substituted phenylalkylamides (e.g. 2 and 3) [11].These results prompted us to determine whether the presence of small and larger carbocycles in the -position of the alkanamido side chain of simple 3-methoxy benzenes has the same effect on melatoninergic potency as in aromatic heterocyclic "frameworks". In the skeleton of the new molecules (5a-h, Scheme 1) the methoxy group present in 2 and 3 has been retained and in their side chain various cycloalkanes have been incorporated.